单位：[1]Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Beijing, China[2]Department of Hepatology, The Third Hospital of Qinhuangdao, Qinhuangdao, Hebei, China[3]Department of Infectious Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China[4]Department of Infectious Disease, Xinxiang Medical University Affiliated Third Hospital, Xinxiang, Henan, China[5]No. 88 Hospital of Chinese People’s Liberation Army (PLA), Jinan, Shandong, China[6]Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China[7]Department of Infectious Disease, China-Japan Friendship Hospital, Beijing, China[8]Department of Infectious Diseases, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China[9]Department of Gastroenterology, The People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China[10]Department of Infectious Diseases, The Third People’s Hospital of Shenzhen, Shenzhen, Guangdong, China深圳市康宁医院深圳医学信息中心[11]Department of Infectious Diseases, The People’s Hospital of Henan Province, Zhengzhou, Henan, China[12]Department of Infectious Disease, The Third Affiliated Hospital of Sun-Yat Sen University, Guangzhou, Guangdong, China中山大学附属第三医院[13]Department of Infectious Diseases, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China江苏省人民医院[14]Department of Infectious Diseases, The Southwest Hospital of Army Medical University, Chongqing, China[15]Yantai Infectious Diseases Hospital, Yantai, Shandong, China[16]Department of Hepatology, Baoding Infectious Diseases Hospital, Baoding, Hebei, China[17]Department of Integrated Traditional Chinese Medicine (TCM) and Western Medicine, Jinan Infectious Diseases Hospital, Shandong University, Jinan, Shandong, China[18]Department of Integrated TCM and Western Medicine in Hepatology, The Sixth People’s Hospital of Shenyang, Shenyang, Liaoning, China[19]Beijing Ditan Hospital, Capital Medical University, Beijing, China[20]Department of Infectious Diseases, Guangzhou Eighth People’s Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China[21]Department of Hepatology, Wuxi No. 5 People’s Hospital, Wuxi, Jiangsu, China[22]The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China[23]Department of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, China[24]Tianjin Second People’s Hospital, Tianjin, China[25]Department of Infectious Diseases, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China北京大学深圳医院深圳市康宁医院深圳医学信息中心[26]No. 305 Hospital of PLA, Beijing, China[27]Department of Hepatology, The Fifth Medical Center of the PLA General Hospital, Beijing, China[28]Department of Infectious Diseases, Shandong Provincial Hospital, Jinan, Shandong, China[29]Department of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan, China四川大学华西医院[30]Department of Hepatology, The Public Hospital Center of Chengdu, Chengdu, Sichuan, China[31]Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China[32]Department of Infectious Diseases, The Affiliated Central Hospital of Shenyang Medical College, Shenyang, Liaoning, China[33]Department of Infectious Diseases, The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China浙江大学医学院附属第一医院[34]Department of Pathology, Beijing Youan Hospital, Capital Medical University, Beijing, China[35]Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China[36]Department of Infectious Diseases, Peking University International Hospital, Beijing, China
Background and Aims: Chronic hepatitis B (CHB) can cause liver fibrosis and lead to cirrhosis and cancer. As the effectiveness of antiviral therapy to reverse liver fibrosis is limited, We aimed to evaluate the effect of An-Luo-Hua-Xian pill (ALHX) on fibrosis regression in CHB patients treated with entecavir (ETV). Methods: Treatment-na??ve patients with CHB were randomly treated with ETV alone or combined with ALHX (ETV+ALHX) between October 1, 2013 and December 31, 2020. Demographic, laboratory, and liver histology data before and after 78 weeks of treatment were collected. The Ishak fibrosis score (F) was used and fibrosis regression required a decrease in F of L.1 after treatment. Results: A total of 780 patients were enrolled, and 394 with a second liver biopsy after treatment were included in the per-protocol population, 132 in ETV group and 262 in ETV+ALHX group. After 78 weeks of treatment, the fibrosis regression rate in the ETV+ALHX group was significantly higher than that of the ETV group at baseline FL.3 patients: 124/211 (58.8%) vs. 45/98 (45.9%), p=0.035. The percentage of patients with a decreased liver stiffness measurement (LSM) was higher in the ETV+ALHX group: 156/211 (73.9%) vs. 62/98 (63.%), p=0.056. Logistic regression analysis showed that ETV combined with ALHX was associated with fibrosis regression [odds ratio (OR)=1.94, p=0.018], and a family history of hepatocellular carcinoma was on the contrary. (OR=0.41, p=0.031). Conclusions: ETV combined with ALHX increased liver fibrosis regression in CHB patients.
基金：
National Science and Technolo-gy Major Project [2013ZX10002005, 2017ZX10203202]
第一作者单位：[1]Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Beijing, China
通讯作者：
通讯机构：[1]Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Beijing, China[36]Department of Infectious Diseases, Peking University International Hospital, Beijing, China[*1]Department of Infectious Diseases and Center for Liver Diseases, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China
推荐引用方式(GB/T 7714)：
Liu Yi-Qi,Zhang Chi,Li Jia-Wen,et al.An-Luo-Hua-Xian Pill Improves the Regression of Liver Fibrosis in Chronic Hepatitis B Patients Treated with Entecavir[J].JOURNAL of CLINICAL and TRANSLATIONAL HEPATOLOGY.2022,doi:10.14218/JCTH.2022.00091.
APA：
Liu, Yi-Qi,Zhang, Chi,Li, Jia-Wen,Cao, Li-Hua,Zhang, Zhan-Qing...&Wang, Gui-Qiang.(2022).An-Luo-Hua-Xian Pill Improves the Regression of Liver Fibrosis in Chronic Hepatitis B Patients Treated with Entecavir.JOURNAL of CLINICAL and TRANSLATIONAL HEPATOLOGY,,
MLA：
Liu, Yi-Qi,et al."An-Luo-Hua-Xian Pill Improves the Regression of Liver Fibrosis in Chronic Hepatitis B Patients Treated with Entecavir".JOURNAL of CLINICAL and TRANSLATIONAL HEPATOLOGY .(2022)
